MaxCyte (MXCT): Debts to Book Capitalization

MaxCyte, Inc. (MXCT) faces risks due to potential cuts in partner innovation spending and pressure from corporate in-house development departments. Meanwhile, experienced management is effectively selling access to its platform, demonstrating strict operational control. Growth relies on expanding the network of B2B contracts with pharma behemoths, and the indicator stands at 0.11. This chart of the current share price clearly illustrates the company's market dynamics.

MXCT MaxCyte, Inc. Debt to Book Value Ratio (07/04/2022 - 10/26/2026)

Summary analytical data breakdowns for MaxCyte Inc. (MXCT)

- price and consensus price forecast:

Stock Price MaxCyte, Inc.|MXCT - Analyst Consensus Forecast

- market capitalization data:

Market Capitalization MaxCyte Inc|MXCT - Full Takeover Company Value

- book capitalization data:

Net Assets per Single Share MaxCyte|MXCT - Accounting Capitalization|Market Value to Book Value Ratio maxcyte.com|MXCT - Company Assets

- debt and liquidity data:

Debt to Equity MaxCyte, Inc.|MXCT - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio MaxCyte, Inc|MXCT - Company Cumulative Indebtedness|Debts to Book Capitalization MaxCyte Inc

Fundamental company analysis:MaxCyte, Inc.

To select the most resilient assets, investors utilize financial leverage filtering to assess a business's dependence on external loans. This metric compares total debt to the book value of equity, allowing this chart of the debt-to-equity ratio to evaluate the risks facing MaxCyte, Inc. (MXCT) as it scales its intelligent software and automates the production of precision systems.

Competitors of MaxCyte, Inc.